Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single Low Dose Primaquine (0.25mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient Subjects

24 Mar 2016

Abstract excerpt

BACKGROUND: Primaquine is the only drug consistently effective against mature gametocytes of Plasmodium falciparum. The transmission blocking dose of primaquine previously recommended was 0.75 mg/kg (adult dose 45 mg) but its deployment was limited because of concerns over haemolytic effects in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency is an inherited X-linked enzymatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Methemoglobinemia and Tumor Lysis Syndrome
Share to Neonatal Health and Biochemistry
Share to Thyroid Disorders and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27010542
DOI: 10.1371/journal.pone.0151898

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single Low Dose Primaquine (0.25mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient SubjectsPMID 27010542Read ↗

G6PD deficiency: global distribution, genetic variants and primaquine therapy.Semantic proximity Read ↗

Pharmacometric assessment of primaquine induced haemolysis in glucose-6-phosphate dehydrogenase deficiencySemantic proximity Read ↗

Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa.Semantic proximity Read ↗

G6<scp>PD</scp> deficiency: a classic example of pharmacogenetics with on‐going clinical implicationsSemantic proximity Read ↗

Therapeutic Efficacy of Artemether-Lumefantrine (AL) plus Single Low Dose Primaquine for the treatment of uncomplicated <i>falciparum</i> malaria in a high transmission setting, Western EthiopiaSemantic proximity Read ↗

Single-Nucleotide Polymorphisms in Glucose-6-Phosphate Dehydrogenase and their Relevance for the Deployment of Primaquine as a Radical Cure for Malaria.Semantic proximity Read ↗

Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.Semantic proximity Read ↗

Genotypes and phenotypes of G6PD deficiency among Indonesian females across diagnostic thresholds of G6PD activity guiding safe primaquine therapy of latent malaria.Semantic proximity Read ↗

Safety Monitoring Experience of Single-low Dose Primaquine Co-administered With Artemether-lumefantrine Among Providers and Patients in Routine Healthcare Practice: a Qualitative Study in Eastern TanzaniaSemantic proximity Read ↗

Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in EthiopiaSemantic proximity Read ↗

Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia.Semantic proximity Read ↗

Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.